EMA Application withdrawn: Balimek (binimetinib) — Pierre Fabre Médicament

View source ↗

Summary

The EMA withdrew the application for Balimek (binimetinib) by Pierre Fabre Médicament for melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Balimek (binimetinib)

Snippet

Status: Application withdrawn. Therapeutic area: Melanoma. MAH: Pierre Fabre Médicament. Decision date: 26/01/2018